PVH
VYGR icon

Psagot Value Holdings’s Voyager Therapeutics VYGR Stock Holding History

Psagot Value Holdings’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-416
Closed -$3K – 631
2023
Q1 		$3K Buy
+416
New +$3.31K ﹤0.01% 392

Other funds holding VYGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Psagot Value Holdings's VYGR Position: Q2 2023 in Review

Psagot Value Holdings sold out of Voyager Therapeutics (VYGR) in Q2 2023, closing a stake of 416 shares — an estimated $3K sold.

Psagot Value Holdings first reported a position in VYGR in Q1 2023 and held it in 1 quarter. The position peaked at $3K in Q1 2023. 106 funds tracked by Wall St. Rank hold VYGR as of Q2 2023.

  • Psagot Value Holdings reported no remaining Voyager Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Psagot Value Holdings sold 416 Voyager Therapeutics shares in Q2 2023, an estimated $3K.
  • Psagot Value Holdings first reported a position in Voyager Therapeutics in Q1 2023 and held it in 1 quarter.
  • Psagot Value Holdings's Voyager Therapeutics position peaked at $3K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2023.

Based on Psagot Value Holdings's 13F filing for Q2 2023, filed 3 Aug 2023.